SCHEMBL6322883

SCHEMBL6322883

Cn1c(=O)c2ncc(C=Cc3cccnc3)nc2n(C)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.46
GRM4 Q14833 1/20 0.44
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 5/20 0.44
TSHR P16473 1/20 0.44
GRM5 P41594 1/20 0.43
MAPT P10636 3/20 0.41
HKDC1 Q2TB90 2/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
JUN P05412 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316381 0.90 KMT2A (0.46) KMT2ANPC1RAB9AMEN1GRM4
SCHEMBL6321029 0.89 KDM4E (0.50) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL6315381 0.88 ALDH1A1 (0.43) ALDH1A1KDM4EMAPTRXFP1GAA
SCHEMBL6318241 0.84 KDM4E (0.50) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL5440337 0.79 KDM4E (0.53) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL6315474 0.79 KDM4E (0.53) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL6316300 0.78 KDM4E (0.44) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL6317891 0.76 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL6323003 0.72 TNF (0.47) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL30596295 0.70 NPC1 (0.72) KMT2ANPC1RAB9AMEN1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US claimed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP disclosed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 KMT2A 1154/4885NPC1 3612/4885RAB9A 3430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.